A note for UK readers

This page explains Brazil’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Do announcements about bringing these medicines to SUS mean access is already universal?

No. An assessment request and plans for incorporation are different from a final funding decision and an operational service.

Check the formulation

Anvisa approved an oral Wegovy formulation in November 2026 for qualifying adults, alongside the previously authorised injection. Approval of a new form does not establish its retail launch or availability. The exact product information remains important.

Public provision is a separate decision

The Ministry of Health submitted a further GLP-1 incorporation request to Conitec in September 2026. Its later communications describe work towards SUS access. These announcements should not be read as a nationwide entitlement to collect a medicine immediately.

The pharmacy retains the prescription

Anvisa states that GLP-1 medicines are subject to medical prescribing with prescription retention. This dispensing rule is a local practical distinction. Claims of convenient access without the appropriate prescription should prompt a check with a licensed pharmacist.

Interpret the headlines for UK care

SUS policy developments concern Brazil. They neither expand NHS eligibility nor establish a UK price reduction. UK readers should distinguish an overseas incorporation proposal from a funded local service, and a new overseas formulation from a UK-authorised option.

Keep these four questions separate

Access

Brazilian prescription-retention requirements

Funding

SUS incorporation work does not itself establish entitlement

Cost context

Projected BRL policy savings are not UK price evidence

Regulatory source

Anvisa

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. Anvisa: oral Wegovy authorisation, November 2026
  2. Ministry of Health: new request for SUS incorporation
  3. Anvisa: registered products and prescription-retention rules
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →